Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-09T06:55:23.597Z Has data issue: false hasContentIssue false

Chapter 13 - Management of prostate cancer in older adults

from Part 2 - Management of solid tumors in older adults

Published online by Cambridge University Press:  05 August 2011

By
Andrew Liman  and
Gurkamal Chatta
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 186 - 200
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jemal, A, Siegel, R, Ward, E. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.CrossRefGoogle ScholarPubMed
Damber, JE, Aus, G. Prostate cancer. Lancet. 2008;371:1710–1721.CrossRefGoogle ScholarPubMed
,National Cancer Institute, Surveillance Epidemiology and End Results (SEER). Cancer Stat Fact Sheets: Cancer of the Prostate. Rockville, MD, 2008.
Abate-Shen, C, Shen, MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14:2410–2434.CrossRefGoogle ScholarPubMed
Gelmann, EP. Complexities of prostate-cancer risk. N Engl J Med. 2008;358:961–963.CrossRefGoogle ScholarPubMed
Tomlins, SA, Bjartell, A, Chinnaiyan, AM. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275–286.CrossRefGoogle ScholarPubMed
Ross, RK, Bernstein, L, Lobo, RA. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887–889.CrossRefGoogle ScholarPubMed
Paris, PL, Kupelian, PA, Hall, JM. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901–905.Google ScholarPubMed
Palapattu, GS, Sutcliffe, S, Bastian, PJ. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26:1170–1181.CrossRefGoogle ScholarPubMed
Ma, J, Li, H, Mucci, L. Prediagnostic body mass index (BMI) and prostate cancer mortality: a 21-year survival analysis in the Physicians'; Health Study. Presented at: Multidisciplinary Prostate Cancer Symposium (ed). Orlando, FL, 2005.Google Scholar
Lippman, SM, Klein, EA, Goodman, PJ. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.CrossRefGoogle Scholar
Thompson, IM, Goodman, PJ, Tangen, CM. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224.CrossRefGoogle ScholarPubMed
Oesterling, JE, Jacobsen, SJ, Chute, CG. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. Jama. 1993;270:860–864.CrossRefGoogle Scholar
Barry, MJ. Screening for prostate cancer–the controversy that refuses to die. N Engl J Med. 2009;360:1351–1354.CrossRefGoogle ScholarPubMed
,Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;149:185–191.CrossRefGoogle Scholar
Prostate cancer. Available at: http://www.cdc.gov/cancer/prostate.
Bill-Axelson, A, Holmberg, L, Ruutu, M. Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer. N Engl J Med. 2005;352:1977–1984.CrossRefGoogle ScholarPubMed
Partin, AW, Kattan, MW, Subong, EN. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–1451.CrossRefGoogle ScholarPubMed
Cooperberg, MR, Broering, JM, Litwin, MS. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393–1401.CrossRefGoogle Scholar
Sun, L, Gancarczyk, K, Paquette, EL. Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urologic Oncology. 2001;6:203–209.CrossRefGoogle Scholar
D'Amico, AV, Chen, MH, Roehl, KA. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135.CrossRefGoogle ScholarPubMed
D'Amico, AV, Moul, JW, Carroll, PR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376–1383.CrossRefGoogle ScholarPubMed
Freedland, SJ, Moul, JW. Prostate specific antigen recurrence after definitive therapy. J Urol. 2007;177:1985–1991.CrossRefGoogle ScholarPubMed
Albertsen, PC, Hanley, JA, Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101.CrossRefGoogle ScholarPubMed
Speight, JL, Roach, M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol. 2005;23:8176–8185.CrossRefGoogle ScholarPubMed
Klotz, L. Active Surveillance for Prostate Cancer: For Whom?J Clin Oncol. 2005;23:8165–8169.CrossRefGoogle ScholarPubMed
Wei, JT, Dunn, RL, Sandler, HM. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557–566.CrossRefGoogle ScholarPubMed
Bolla, M, Reijke, TM, Zurlo, A, Collette, L. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. Front Radiat Ther Oncol. 2002;36:81–86.CrossRefGoogle ScholarPubMed
Messing, EM, Manola, J, Yao, J. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472–479.CrossRefGoogle ScholarPubMed
Pilepich, MV, Winter, K, John, MJ. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252.CrossRefGoogle ScholarPubMed
D'Amico, AV, Manola, J, Loffredo, M. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821–827.CrossRefGoogle ScholarPubMed
Stephenson, AJ, Shariat, SF, Zelefsky, MJ. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332.CrossRefGoogle ScholarPubMed
Loblaw, DA, Virgo, KS, Nam, R. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596–1605.CrossRefGoogle ScholarPubMed
Mohler, JL, Gregory, CW, Ford, OH. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–448.CrossRefGoogle ScholarPubMed
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235–246.CrossRef
Harle, LK, Maggio, M, Shahani, S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006;4:687–696.Google ScholarPubMed
Michaelson, MD, Cotter, SE, Gargollo, PC. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196–213.CrossRefGoogle ScholarPubMed
Smith, MR, McGovern, FJ, Zietman, AL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–955.CrossRefGoogle ScholarPubMed
Keating, NL, O'Malley, AJ, Smith, MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456.CrossRefGoogle ScholarPubMed
Boccon-Gibod, L, Hammerer, P, Madersbacher, S. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 2007;100:738–743.CrossRefGoogle ScholarPubMed
Feldman, BJ, Feldman, D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.CrossRefGoogle ScholarPubMed
Montgomery, RB, Mostaghel, EA, Vessella, R. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–4454.CrossRefGoogle ScholarPubMed
Attard, G, Reid, AHM, Yap, TA. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. J Clin Oncol. 2008;26:4563–4571.CrossRefGoogle ScholarPubMed
Tannock, IF, Wit, R, Berry, WR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.CrossRefGoogle ScholarPubMed
Saad, F, Gleason, DM, Murray, R. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882.CrossRefGoogle ScholarPubMed
Ries, L, Harris R. 2001–2005 NCI SEER cancer statistics review. Ann Intern Med. 2002;13:917.Google Scholar
Kattan, M, Eastham, J, Stapleton, A. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 1998;90: 766–771.CrossRefGoogle ScholarPubMed
Bolla, M, Collette, L, Blank, L. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106.CrossRefGoogle ScholarPubMed
Shipley, WU, Kaufman, DS, Tester, WJ. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003;97:2115–2119.CrossRefGoogle ScholarPubMed
Messing, EM, Manola, J, Sarosdy, M. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788.CrossRefGoogle ScholarPubMed
Sharifi, N, Gulley, JL, Dahut, WL. Androgen Deprivation Therapy for Prostate Cancer. JAMA. 2005;294:238–244.CrossRefGoogle ScholarPubMed
Higano, CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61:32–38.CrossRefGoogle ScholarPubMed
Greenspan, SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab. 2008;93:2–7.CrossRefGoogle ScholarPubMed
Scher, HI, Halabi, S, Tannock, I. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–1159.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×